Results 1 to 4 of 4

Thread: Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal C

  1. #1

    Thumbs up Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal C

    We remain extremely excited about the potential for OPC1 to provide enhanced motor recovery to patients with spinal cord injuries. We are not aware of any other investigative therapy for SCI which has reported as encouraging clinical outcomes as OPC1, particularly with continued improvement beyond 1 year?


    https://www.businesswire.com/news/ho...Clinical-Study

  2. #2
    Very interesting! I hope they test it on people with chronic injuries too. Drug's given Orphan Drug status, a plus....

  3. #3
    OPC is for an acute stage up to 42 days after injury. They do not want to perform well in the chronic niche in rodents.

  4. #4
    Senior Member
    Join Date
    May 2005
    Location
    Pakistan
    Posts
    1,177
    Quote Originally Posted by GRAMMY View Post
    OPC is for an acute stage up to 42 days after injury. They do not want to perform well in the chronic niche in rodents.
    Dear Grammy any updates from Leif Havton???

Similar Threads

  1. Replies: 4
    Last Post: 08-29-2014, 04:23 PM
  2. Replies: 2
    Last Post: 06-05-2014, 10:15 PM
  3. Replies: 2
    Last Post: 05-23-2012, 02:40 AM
  4. Replies: 12
    Last Post: 07-12-2011, 02:09 AM
  5. Replies: 0
    Last Post: 07-07-2011, 08:59 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •